medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2012, Number 1

<< Back

VacciMonitor 2012; 21 (1)

Immunotherapeotical alternatives for the atherosclerosis treatment

Delgado L, Vázquez AM, Fernández E

Language: Spanish
References: 38
Page: 38-42
PDF size: 75.28 Kb.


ABSTRACT

Atherosclerosis represents the first cause of death in the western world. Although there are several hypothesis which explain its pathogenesis, one of the most recognized is the autoimmune hypothesis. The activation of the immunological system against different atherogenic stimulus induces a reaction which may affect the vascular endothelium with the consequent atherogenic lesion development. The design of new therapeutic strategies, among them vaccines, represents a tool with promissory result in atherosclerosis treatment. Taking into account these antecedents, in the present work it was examined the state of the art on the immunomodulation of this chronic disease.


REFERENCES

  1. Paim BA, Velho JA, Castillo RF, Oliveira H, Vercesi AE. Oxidative stress in hypercholesterolemic LDL (low density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADP-linked substrates and is partially reversed by citrate replacement. Free Radic Biol Med 2008;44: 444-51.

  2. Anuario Estadístico de Cuba. La Habana: Dirección Nacional de Estadística de Cuba; 2010. Disponible en: http://files.sld.cu/ dne/tiles/2011/04/anuario-2010-e-sin-graficos1.pdf.

  3. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002;8:1218-26.

  4. Tavori H, Aviram M, Khatib S, Musa R, Nitecki S, Hoffman A, et al. Human carotid atherosclerotic plaque increases oxidative state of macrophages and low density lipoproteins, whereas paraoxonase (PON1) decreases such atherogenic effects. Free Radic Biol Med 2009; 46:607-15.

  5. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8:1211-27.

  6. Bourlon R A, López M. Aterosclerosis y lesión endotelial: ¿proceso irreversible? Med Int Mex 2010;26:590-6.

  7. Steinberg D, Parthasarathy S, Crew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low density lipoprotein that increase its atherogenecity. N Engl J Med 1989; 320:915- 24.

  8. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-61.

  9. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-26.

  10. Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 2008;201: 17-32.

  11. Delgado L. Role of the immunological system in the initiation and progression of atherosclerosis. Pharmacologyonline 2010; 2: 282-97.

  12. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281-91.

  13. Mackay IR, Leskovsek N, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimm 2008;30:5-11.

  14. Doherty TM, Fisher EA, Arditi M. TLR signaling and trapped vascular dendritic cells in the development of atherosclerosis. Trends Immunol 2006;27:222-7.

  15. Xiao Q, Mandal K, Schett G. Association of serum-soluble heat shock protein 60 with carotid atherosclerosis. Stroke 2005; 36:2571-6.

  16. Goncalves I, Nitulescu M, Ares MPS, Nordin G, Jansson B, Li ZC, et al. Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions. Atherosclerosis 2009;205:96-100.

  17. Van Eden W. Immunoregulation of autoimmune diseases. Hum Immunol 2006; 67:446-57.

  18. Kohl J. The role of complement in danger sensing and transmission. Immunol Res 2006;34: 157-76.

  19. Knoflach M, Kiechl S, Mayrl B, Kind M, Gaston JSH, van der Zee R, et al. T-cell reactivity against HSP60 relates to early but not advanced atherosclerosis. Atherosclerosis 2007;195:333- 8.

  20. Chou MY, Hartvigsen K, Hansen LF, Fogelstrand L, Shaw PX, Boullier SA, et al. Oxidation-specific epitopes are important targets of innate immunity. J Int Med 2008;263:479-88.

  21. Matsuura E, Kobayashi K, Tabuchi M, López LR. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Progr Lipid Res 2006;45:466-86.

  22. Conrad K, Bachmann MP, Matsuura E, Shoenfeld Y. From animal model to human genetics: research on the induction and pathogenicity of autoantibodies. Autoimm Rev 2005; 4:178- 87.

  23. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281-91.

  24. Den Dekker WK, Chreng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010; 209:314-20.

  25. Schoenfeld Y. Atherosclerosis as autoimmune condition. Harefuah 2001;140:720-2.

  26. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134(1):33-46.

  27. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 2006; 114:1977-84.

  28. Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol 2010; 134:55- 65.

  29. Schonbek U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci 2000;97:7458-63.

  30. Lutgens E, Clentjens KB, Heeneman S, Koteliansky VE, Burkly MJ, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000; 97:7464-9.

  31. Wanrooij EJ, Puijvelde GH, Vos P, Yageta H, Berkeld TJ, Kuiper J. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptordeficient mice. Arterioscler Thromb Vasc Biol 2007;27:204-10.

  32. Steppich BA, Moog P, Matissek C. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2007;190:443-51.

  33. Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, Yano J, et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006; 189: 83-90.

  34. Schiopu A, Frendéus B, Jansson B, Soderberg I, Ljungcrantz I, Araya Z, et al. Recombinant antibodies to an oxidized lowdensity lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1-/- /low density lipoprotein receptor mice. J Am Coll Cardiol 2007; 50:2313-8.

  35. Chyu KY, Zhao X, Reyes O, Stephanie BM, Dimayuga PC, Yano J, et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (_/_) mice. Biochem Biophys Res Commun 2005;338:1982-9.

  36. Hauer AD, Habets KLL, van Wanrooij EJA, de Vos P, Krueger J, Reisfeld RA, et al. Vaccination against TIE2 reduces atherosclerosis. Atherosclerosis 2009; 204:365-71.

  37. White CR, Data G, Zhang Z, Gupta H, Garber DW, Mishra VK, etal. HDL Therapy for Cardiovascular Diseases: the Road to HDL Mimetics. Curr Atheroscler Rep 2008;10:405-12.

  38. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Therap 2006;111:893-908.




2020     |     www.medigraphic.com